Carmat SA engages in the developing of implantable orthotropic and biocompatible artificial heart. Its artificial heart is intended for patients with advanced cardiac insufficiency that is ineligible for a transplant and have exhausted all medication alternatives. The firm also develops electrical power supply system and telediagnostics system. The company was founded by Pouletty Philippe and Alain Carpentier on June 25, 2008 and is headquartered in Vélizy Villacoublay, France.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company